GlobeNewsWire
30 Dec 2025, 13:00 UTC · 43w ago
Verdict
Headline takes no side. We score DNLI +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
The FDA is conducting a Priority Review of the Biologics License Application (BLA) for tividenofusp alfa, with a decision expected by April 5, 2026.
More positive than 99% of claims this week
Phase 1/2 data showed that tividenofusp alfa substantially reduced CNS and peripheral biomarkers and normalized heparan sulfate levels in both cerebrospinal fluid and urine.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 92% of claims this week
Tividenofusp alfa is designed to cross the blood-brain barrier, potentially becoming the first FDA-approved enzyme replacement therapy to treat the brain in Hunter syndrome.
More positive than 85% of claims this week
The results from the Phase 1/2 study have been published in The New England Journal of Medicine.
More positive than 48% of claims this week
Denali intends to leverage its TransportVehicle platform to deliver other antibodies and oligonucleotides for various brain-impacting diseases.
More positive than 48% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company published positive Phase 1/2 trial results for tividenofusp alfa and is awaiting a Priority Review for FDA approval.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2d ago
+14.2%
Price agrees with the score
$18.94 vs $16.58 close before publication (Dec 29) · not market-adjusted
DNLI chart →
